Cohance Lifesciences Limited (BOM:543064)

Market Cap	174.83B -47.8%
Revenue (ttm)	21.42B +70.1%
Net Income	1.06B -56.0%
EPS	n/a
Shares Out	n/a
PE Ratio	164.58
Forward PE	69.98
Dividend	n/a
Ex-Dividend Date	n/a

Volume	14,058
Open	458.90
Previous Close	446.75
Day's Range	446.85 - 459.55
52-Week Range	267.85 - 917.50
Beta	n/a
Analysts	Hold
Price Target	508.33 (+11.22%)
Est. Earnings	Nov 5, 2026

About Cohance Lifesciences

Cohance Lifesciences Limited engages in the contract research, development, and manufacturing of new chemical entity (NCE) based intermediates, active pharmaceutical ingredients (API), specialty chemicals, and formulated drugs in India, the United States, Europe, and internationally. The company offers small molecule APIs, advanced intermediates, and starting materials; antibody drug conjugates; high-purity oligonucleotide building blocks comprising phosphoramidites, nucleosides, pseudouridine, NTPs, CAP reagents, GalNAc conjugates, and fluores...

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• Founded: 1989
• Employees: 1,212
• Stock Exchange: Bombay Stock Exchange
• Ticker Symbol: 543064

Financial Performance

In fiscal year 2026, Cohance Lifesciences's revenue was 22.69 billion, a decrease of -13.03% compared to the previous year's 26.09 billion. Earnings were 1.79 billion, a decrease of -63.22%.

Analyst Summary

According to 9 analysts, the average rating for 543064 stock is "Hold." The 12-month stock price target is ₹508.33, which is an increase of 11.22% from the latest price.

Price Target

₹508.33

(11.22% upside)

Analyst Consensus: Hold

Data Source: S&P Global Market Intelligence

Fundamental and historical data is provided by S&P Global Market Intelligence.

Last checked:

Oct 7, 2026

Data Sources Report a data error